AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00663819 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement
Description: Colorectal, coloanal, and ileoanal anastomotic staple line reinforcement with GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement configured for circular stapler
Study NCT00663819 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Staple line without reinforcement
Description: colorectal and coloanal anastomotic staple line without reinforcement
Study NCT04687878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: twice a day, intranasally, every day for 12 weeks
Study NCT00869349 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IFS
Description: The program will begin with a half day orientation to meet the trained professional coaches and other patients enrolled in the program. Following the orientation there will be group meetings of 8-10 RA patients every other week for twelve weeks with one of the trained coaches. In the weeks patients do not meet with the group, patients will have individual coaching sessions. The group meetings will last approximately 90 minutes and the individual meetings will last 50 minutes. A maintenance program will follow with bimonthly coaching sessions and a group meeting once a month over the next six months.~Three, six and nine months after the beginning of the program, patients will return to the hospital to complete the same research questionnaire and physical examination they received at baseline.
Study NCT03580356 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ligelizumab
Description: Liquid in vial
Study NCT00869349 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: The intervention for the controls includes an initial meeting with a health professional. Once a month for 9 months, patients will received educational material and a follow-up phone call to ask if the patient received the information and to answer any questions about the material.
Study NCT03580356 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Lyophilized powder for solution in vial
Study NCT03580356 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid in vial
Study NCT01279278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Co-signed letter
Description: Patients receive a personalized letter co-signed by their general practitioner and the medical coordinator of ADECA.
Study NCT01279278 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Classical Letter
Description: Patients receive classical letter signed by the coordinator doctor of ADECA
Study NCT03387995 — intervention group
Intervention type: DEVICE
Intervention: LVIS stent
Description: The paitents treated by LVIS stent implantation.
Study NCT03387995 — intervention group
Intervention type: DEVICE
Intervention: Solitaire stent
Description: The paitents treated by Solitaire stent implantation.
Study NCT03387995 — intervention group
Intervention type: DEVICE
Intervention: Enterprise stent
Description: The paitents treated by Enterprise stent implantation.
Study NCT01785732 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Renal Denervation
Description: Sympathetic renal denervation via renal arteries
Study NCT01899690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antibiotic
Description: Patients after breast reconstruction with implant/tissue expander reconstruction who receive the intervention will be prescribed with a 7 day course of postoperative antibiotics.
Study NCT02442362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel+oxaliplatin+fluorouracil
Description: Patients treated with paclitaxel+oxaliplatin+fluorouracil: paclitaxel (135 mg/m2 iv) on day 1, oxaliplatin (100 mg/m2 iv) on day 1, fluorouracil (500 mg/m2 continuous iv) on day 1-5twice/day for body surface area between 1.25 and 1.50 m2 orally) on days 1-14.
Study NCT02442362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin+S1
Description: Patients treated with oxaliplatin+S1: oxaliplatin (130 mg/m2 iv) on day 1 and S-1 (40 mg twice/day for body surface area \< 1.25 m2 and 60 mg twice/day for body surface area between 1.25 and 1.50 m2 orally) on days 1-14
Study NCT01541124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid
Description: 10 mg/pill, po, each 6h, during 6m
Study NCT03258489 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous nervous electric stimulation (TENS)
Description: TENS (Frequency 10 Hz or 100Hz /duration 200μs, Endophasys nms 0501® model, KLD Biosystems, Amparo, SP, Brazil) will be applied with intensity between 1 to 60 mA and the current will be adjusted every 5 minutes at the sensory threshold level muscle contraction or according to the tolerance to the stimulus informed by the volunteers. TENS will be applied in bilateral paravertebral region of C7 to T4 or long the brachial plexus and sciatic plexus.
Study NCT03258489 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interferential electrical stimulation (IES)
Description: The IES (Endophasys nms 0501®, KLD Biosystems, Amparo, SP, Brazil) will be applied in continuous mode with biphasic pulses. Bipolar electrodes with slope of 1/5/1. The rest of the parameters will be set to 4000 Hz, AMF of 100 Hz and the AMF variation of 25 Hz. The effect of the current will be adjusted by the intensity, it should produce paresthesia stimuli, without pain and below the motor threshold. Adhesive electrodes (MultiStick®, Axelgaard Manufacturing CO, Ltd, Fallbrook, CA, USA) will be housed in the paravertebral region, between C7 (Channel 1) and T4 (Channel 2). (SANTOS et al., 2013)
Study NCT03258489 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TENS and IES Placebo
Description: Same protocol without electrical output.
Study NCT02562794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Strengthening Intervention-Refugees
Description: This study aims to design a preventive intervention for at-risk refugee children and families. The intervention is focused on strengthening core family resources and promoting resilience and healthy parent-child interactions.
Study NCT00891254 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implant of a prosthetic mesh
Description: A prosthetic mesh will be implanted either intraperitoneally or in the on-lay (supra-fascial) position depending on the arm of the study
Study NCT04563793 — intervention group
Intervention type: DEVICE
Intervention: Superion™ IDS
Description: All patients to receive IDS for the treatment of moderate Lumbar Spinal Stenosis symptoms.
Study NCT03178864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 20 mg daily (15 mg daily in participants with a CrCl 30-49 mL/min as per the Cockroft-Gault equation)
Study NCT03178864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Accepted standard of care as per American Heart Association/American Stroke Association Guidelines (initial use of unfractionated heparin or low-molecular weight heparin with transition to an oral vitamin K antagonist or continuation with low-molecular weight heparin) with choice of agent at the treating physician's discretion.
Study NCT04189211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8001
Description: IV infusions.
Study NCT06336850 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound-Guided Portal Pressure Gradient Measurement
Description: The endoscopic ultrasound (EUS)-guided 25G fine needle aspirate (FNA) needle procedure is a straightforward minimally invasive technique for direct portal pressure measurements.
Study NCT04037605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole Pill (also known as nizoral)
Description: Ketoconazole pill is taken 4 times per inpatient visit
Study NCT04037605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix
Description: Ganirelix subcutaneous injection is administered twice per inpatient visit
Study NCT04037605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Pill
Description: Dexamethasone pills is taken twice per inpatient visit
Study NCT04037605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone injection
Description: Dexamethasone IV injection is given twice per inpatient visit
Study NCT04037605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cosyntropin Injectable Product
Description: Cosyntropin injection is given twice per inpatient visit
Study NCT04037605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Luteinizing Hormone (also known as luveris)
Description: Recombinant Human Luteinizing Hormone is given as 6 IV infusion pulses per inpatient visit
Study NCT04037605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Injection (also known as solu-cortef)
Description: Hydrocortisone IV push is given twice per inpatient visit
Study NCT04037605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadorelin (also known as Lutrepulse)
Description: Gonadorelin IV injection is given twice per inpatient visit
Study NCT04037605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticorelin (also known as Acthrel)
Description: Corticorelin IV injection is given twice per inpatient visit
Study NCT03387995 — intervention group
Intervention type: DEVICE
Intervention: Neuroform stent
Description: The paitents treated by Neuroform stent implantation.
Study NCT04037605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Placebo for Ketoconazole are given 4 times per inpatient visit
Study NCT04037605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Solution
Description: Saline Solution (Placebo) for Dexamethasone IV injection or hydrocortisone IV injection given up to four times per inpatient visit
Study NCT03387995 — intervention group
Intervention type: DEVICE
Intervention: Flow diverter (FD) stent
Description: The paitents treated by Enterprise FD implantation.
Study NCT04037605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline solution for injection
Description: Saline Solution (placebo) for ganirelix subcutaneous injection
Study NCT02281786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to RO6926496
Study NCT02281786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6926496
Description: single, ascending dose, intravenous administration
Study NCT02889484 — intervention group
Intervention type: PROCEDURE
Intervention: Lumbar disc hernia surgery
Study NCT02964351 — intervention group
Intervention type: BIOLOGICAL
Intervention: High PSA levels
Study NCT01602874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigecycline
Description: Subject with cIAI:~Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12 hours, metronidazole placebo IV will be administered every 8 hours. In addition, at the discretion of the investigator, an aminoglycoside placebo IV may also be administered.
Study NCT01602874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigecycline
Description: Subject with CAP:~IV therapy period: Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12h. At the discretion of the investigator oral clarithromycin placebo may be given every 12h.~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).
Study NCT01602874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside
Description: Subject with cIAI:~Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12 hours, metronidazole 10 mg/kg (maximum of 1 g/dose) IV will be administered every 8 hours.~In addition, at the discretion of the investigator, an aminoglycoside IV (adjusted dose if necessary) may also be given.
Study NCT01602874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAP: Ceftriaxone, plus if applicable oral clarithromycin
Description: Subject with CAP:~IV therapy period: Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12h. At the discretion of the investigator, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).
Study NCT04566211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (panto+amox+clar+metr)+(panto+amox)
Description: a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 3-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
Study NCT04566211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pantoprazole+bismuth+amox+clar
Description: pantoprazole 40 mg twice daily, bismuth subcitrate 240 mg twice daily, and amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily for 10 days
Study NCT02938871 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Synbiotic
Description: The patients of this group will receive 6 grams of synbiotic composition, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
Study NCT02938871 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The patients of this group will receive 6 grams of maltodextrin, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
Study NCT04774107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P1101 + Ribavirin
Description: P1101 400 µg SC
Study NCT03638531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Description: Anodal tDCS will be applied over the FDI muscle representational area of the motor cortex for 25 minutes in combination with the two motor tasks (precision grip task and handwriting task).
Study NCT03638531 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM tDCS
Description: SHAM tDCS will be applied over the FDI muscle representational area of the motor cortex for 25 minutes in combination with the two motor tasks (precision grip task and handwriting task).
Study NCT00422149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUBLIVAC® Grasses/Placebo treatment
Description: SUBLIVAC® Grasses/Placebo treatment
Study NCT00422149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SUBLIVAC® Grasses/Placebo treatment
Description: SUBLIVAC® Grasses/Placebo treatment
Study NCT00422149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUBLIVAC® Grasses treatment
Description: SUBLIVAC® Grasses treatment
Study NCT00422149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Placebo treatment
Study NCT04418011 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: The present study aims to use both repetitive transcranial magnetic stimulation (rTMS) and intermittent theta burst stimulation (iTBS), safe and effective forms of neuromodulation, to target the neural circuitry of social cognitive (SCog) impairments in people with SSDs. Treatment sessions will be administered five days per week for two weeks.~Other Name: MagPro X100 or R30 (Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)
Study NCT04418011 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (Intermittent Theta Burst Stimulation)
Description: The present study aims to use both repetitive transcranial magnetic stimulation (rTMS) and intermittent theta burst stimulation (iTBS), safe and effective forms of neuromodulation, to target the neural circuitry of social cognitive (SCog) impairments in people with SSDs. Treatment sessions will be administered five days per week for two weeks.~Other Name: MagPro X100 or R30 (Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)
Study NCT04418011 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (Sham)
Description: Other Name: MagPro X100 or R30(Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)
Study NCT03548506 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omnidirectional Deep Brain Stimulation of STN
Description: Deep Brain Stimulation
Study NCT03548506 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Directional Deep Brain Stimulation of STN
Description: Deep Brain Stimulation
Study NCT00842946 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure w/ Acceptance-Based Rationale
Description: Treatment focuses on the ineffectiveness of participants' past attempts to control or reduce their anxiety in public speaking situations. Acceptance of one's private experiences (thoughts, feelings, sensations) will be introduced. Willingness to experience unwanted thoughts and feelings while simultaneously engaging in valued activities, especially those related to public speaking, is stressed. Techniques designed to foster psychological acceptance are practiced prior to and during exposure exercises, as well as assigned for homework between sessions.
Study NCT00842946 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure w/ Habituation-Based Rationale
Description: Exposure to feared public speaking situations are accompanied by explanations of behavioral principles, including classical/operant conditioning and habituation. The process of associating public speaking situations with unwanted feelings of anxiety will be discussed, as well as negative reinforcement of escape and avoidance behaviors. The underlying principle of habituation is reviewed. When engaging in exposure exercises (both in session and assigned homework exercises), participants will be encouraged to remain in the feared speaking situation until their subjective ratings of anxiety decrease.
Study NCT04319380 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus/diphtheria toxoids
Description: One dose of tetanus/diphtheria toxoids vaccine (June) in year 1 and year 2.
Study NCT04319380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SMC with SP+AQ
Description: Year 1 and 2 (2020/21) Four cycles of SMC (SP+AQ) (July, August, September, October). One cycle of SMC consisting of sulphadoxine - pyrimethamine (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3.
Study NCT03199586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP-G2-044
Description: capsule
Study NCT00856284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets
Study NCT00856284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin tablets
Study NCT00856284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin tablets
Study NCT00856284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glipizide
Description: Glipizide tablets
Study NCT04537767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: The protocol required a titrated esmolol infusion commenced at 25 mg/ h, with an upper dose limit of 2000 mg/h, to maintain the HR between 75 and 90 bpm in ES group. The control group were treated with placebo.
Study NCT04537767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00536601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00536601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00536601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: Given IV
Study NCT00536601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV
Study NCT00536601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV
Study NCT00536601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV